Auro Laboratories (AUROLAB) | Stock Overview & Key Data
Auro Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹245.00
High: ₹264.00
on August 22, 2025
52 Week Range
Low: ₹170.00
High: ₹303.00
on February 17, 2025
on July 17, 2025
All-Time High: ₹307.20 on May 6, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR1.6B
EPS
2.95
P/E Ratio (TTM)
85.07
Forward P/E
N/A
P/B Ratio
3.65
PEG Ratio
N/A
Div. Yield
N/A
ROE
4.28%
Beta
0.195
Debt to Equity
104.76
Financial Highlights
Profitability
Gross Margin
31.59%
Operating Margin
-8.69%
Profit Margin
5.96%
Returns and Earnings
Return on Assets (TTM)
1.86%
Return on Equity (TTM)
4.28%
EBITDA
INR40.6M
Net Income (TTM)
INR9.8M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR26.40
Quarterly Revenue Growth (YoY)
-51.50%
Quarterly Earnings Growth (YoY)
-32.24%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Auro Laboratories AUROLAB | 1.56B Small-cap | -2.98% | -9.91% | 0.49% | 10.14% | -2.74% | 27.16% | 230.13% | 351.23% |
| Sun Pharmaceutical SUNPHARMA | 3.92T Large-cap | 0.07% | -2.94% | -5.16% | -0.08% | -13.09% | -7.63% | 86.35% | 195.13% |
| Divi's Laboratories DIVISLAB | 1.64T Large-cap | -1.70% | -9.87% | -8.00% | 4.71% | -0.74% | 24.14% | 68.03% | 84.18% |
| Sun Pharma Advanced SPARC | 47.77B Small-cap | 3.43% | -9.83% | -12.50% | 12.07% | -27.72% | -34.90% | -37.57% | -23.72% |
| Aarti Drugs AARTIDRUGS | 44.80B Small-cap | -3.22% | -13.59% | -0.59% | 21.36% | 3.40% | -16.47% | 7.52% | -35.72% |
| Sequent Scientific SEQUENT | 44.30B Small-cap | -0.44% | -6.77% | -2.09% | 9.71% | -5.23% | 5.57% | 52.75% | 30.80% |
Ownership & Short Interest
Insider Ownership
59.73%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
4K
Average 90-Day Volume
6K
Auro Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Auro Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AUROLAB's 52-week high and low?
- In the last 52 weeks, Auro Laboratories reached a high of ₹303.00 (on July 17, 2025) and a low of ₹170.00 (on February 17, 2025).
- What is the market cap and P/E ratio for AUROLAB?
- Curious about Auro Laboratories's size and valuation? Its market capitalization stands at 1.56B. When it comes to valuation, the P/E ratio (trailing twelve months) is 85.07, and the forward P/E (looking ahead) is N/A.
- Does AUROLAB pay dividends? If so, what's the yield?
- As for dividends, Auro Laboratories isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Auro Laboratories's main competitors or similar companies to consider before investing?
When looking at Auro Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.92T Healthcare Drug Manufacturers - Specialty & Generic -7.63% 86.35% Divi's Laboratories
DIVISLAB1.64T Healthcare Drug Manufacturers - Specialty & Generic 24.14% 68.03% Sun Pharma Advanced
SPARC47.77B Healthcare Drug Manufacturers - Specialty & Generic -34.90% -37.57% Aarti Drugs
AARTIDRUGS44.80B Healthcare Drug Manufacturers - Specialty & Generic -16.47% 7.52% Sequent Scientific
SEQUENT44.30B Healthcare Drug Manufacturers - Specialty & Generic 5.57% 52.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Auro Laboratories Limited? (e.g., ROE, Debt/Equity)
- To get a sense of Auro Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.28%, the Debt to Equity ratio from the most recent quarter is 104.76, and its Gross Profit Margin stands at 31.59%.
- What is the recent revenue and earnings growth for AUROLAB?
- Looking at Auro Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR165M. Compared to the same quarter last year (YoY), quarterly revenue grew by -51.50%, and quarterly earnings saw a YoY growth of -32.24%.
- How much of AUROLAB stock is held by insiders and institutions?
- Wondering who owns Auro Laboratories stock? Company insiders (like executives and directors) hold about 59.73% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.